- The FDA has approved Sol-Gel Technologies Ltd's SLGL first proprietary drug product, Twyneo (tretinoin/benzoyl peroxide) cream, 0.1%/3%, indicated for acne vulgaris in adults and pediatric patients nine years of age and older.
- Twyneo uses Sol-Gel's patented technology to entrap tretinoin, a retinoid, and benzoyl peroxide within silica-based microcapsules to stabilize tretinoin from being degraded by benzoyl peroxide and to release each of the active drug ingredients slowly.
- The product is patent-protected until 2038.
- Sol-Gel has partnered with Galderma to commercialize Twyneo in the U.S.
- Sol-Gel expects to receive a regulatory milestone payment in conjunction with the approval.
- Price Action: SLGL shares are up 2.56% at $12.42 during the market session on the last check Tuesday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
